GSE232944 APC CTNNB1 overexpression HT29 1 v 2 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE232944_APC_CTNNB1 overexpression_HT29_1_v_2_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE232944_APC_CTNNB1 overexpression_HT29_1_v_2_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE232944_APC_CTNNB1 overexpression_HT29_1_v_2_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE232944_APC_CTNNB1 overexpression_HT29_1_v_2_human_up.

Results found

Linked to

 

Label

Description

 

Gene

valyl-tRNA synthetase 1

Gene

WD repeat domain 46

Gene

MIR4435-2 host gene

Gene

lung cancer associated transcript 1

Gene

tripartite motif containing 31

Gene

ABCF2-H2BK1 readthrough

Gene

AFAP1 antisense RNA 1

Gene

long intergenic non-protein coding RNA 857

Gene

long intergenic non-protein coding RNA 942

Gene

long intergenic non-protein coding RNA 1559

  • Gene

    valyl-tRNA synthetase 1


  • Gene

    WD repeat domain 46



  • Gene

    lung cancer associated transcript 1


  • Gene

    tripartite motif containing 31


  • Gene

    ABCF2-H2BK1 readthrough


  • Gene

    AFAP1 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 857


  • Gene

    long intergenic non-protein coding RNA 942


  • Gene

    long intergenic non-protein coding RNA 1559

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.